Obesity drug sales surge at Novo Nordisk - Financial Times

1 day ago · Obesity drug sales surge at Novo Nordisk on whatsapp (opens in a new ... Sales of obesity treatments rose 56 per cent to DKr65.1bn. ... Diluted earnings per share were up 22 …

CouponFollow Extension

25%
OFF

Novo Nordisk Earnings: Surge In Obesity Treatments

3 weeks from now

3 hours ago · What We Thought of Novo Nordisk Q4 Earnings Novo Nordisk grew its top line and operating profit by 25% in 2024, as insulin rebate adjustments drove performance ahead of …

morningstar.co.uk

$150
OFF

Wegovy Sales Double To Boost Novo Nordisk's Fourth Quarter As …

3 weeks from now

1 day ago · Novo Nordisk was the first-mover in an obesity drug market that some analysts forecast could be worth about $150 billion by the early 2030s, but is now facing fierce …

reuters.com

38%
OFF

Novo Nordisk’s Earnings Surge On Frenzy For Obesity Drugs

3 weeks from now

Nov 2, 2023 · Novo Nordisk A/S sales surged in the third quarter as demand continued unabated for its obesity and diabetes blockbusters. Revenue rose 38% to 58.73 billion kroner ($8.3 …

financialexpress.com

4%
OFF

Novo Nordisk Stock Jumps On Q4 Beat: Retail Brushes Off Slower …

3 weeks from now

NYSE-listed shares of Novo Nordisk surged 4% on Wednesday morning after the Danish pharmaceutical giant posted better-than-expected fourth-quarter earnings. The company …

msn.com

26%
OFF

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price …

3 weeks from now

22 hours ago · Novo Nordisk A/S today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn and a 26% rise in operating profit to ~$17.91bn for 2024. The …

seekingalpha.com

5%
OFF

Novo Nordisk Stock Notches Another Record As Obesity …

3 weeks from now

Apr 13, 2023 · But Novo remains alone on the market with approved obesity treatments. Today, Novo Nordisk stock has a strong Relative Strength Rating of 95, putting shares in the top 5% …

investors.com

22%
OFF

Novo Nordisk Shares Surge On New Obesity Drug Results — Update

3 weeks from now

Jan 24, 2025 · Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their bodyweight in a …

morningstar.com

22%
OFF

Novo Nordisk Shares Surge On New Obesity Drug Results

3 weeks from now

Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial.

wsj.com

22%
OFF

Novo Nordisk Shares Surge On New Obesity Drug Results

3 weeks from now

Jan 24, 2025 · Novo Nordisk shares rose sharply after the Danish pharmaceutical giant said an experimental weight-loss shot showed patients lost 22% of their bodyweight in a clinical trial. …

morningstar.com

$1
OFF

Sales Of Obesity Drugs Push Novo Nordisk, Eli Lilly To Top In Q2

3 weeks from now

Aug 15, 2023 · Novo Nordisk's Wegovy soars, crossing $1B mark in a single quarter A successful quarter for J&J prompted the company to lift the window of its 2023 revenue by nearly $1 …

fiercepharma.com

1%
OFF

Novo Nordisk Surges As Next-Gen Obesity Drug Outperforms

3 weeks from now

Jan 24, 2025 · In March 2024, Novo Nordisk said patients who took a daily pill of amycretin lost 13.1% of their body weight, topping the placebo group by 11.9%. But that came alongside …

investors.com

5%
OFF

Novo Nordisk Shares Surge As Wegovy Sales Drive Profit Beat

3 weeks from now

1 day ago · Novo Nordisk shares rose 4.5% after a strong Q4 profit beat, driven by high demand for obesity drug Wegovy, despite forecasting slower sales growth for 2025.

invezz.com

FAQs about Obesity drug sales surge at Novo Nordisk - Financial Times Coupon?

How did Novo Nordisk beat revenue expectations in 2024?

Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn), driven by sales of obesity and diabetes drugs, particularly in the US. ...

Why is Novo Nordisk a cautious stock?

Novo Nordisk attributed the cautious outlook to growing competition and pricing pressures in the booming obesity and diabetes drug market. The company’s obesity drug Wegovy continued its meteoric rise, with sales surging 107% year-on-year to 19.87 billion kroner ($2.76 billion) in the fourth quarter. ...

Is Novo Nordisk a breakthrough in the fight against obesity?

Experts have therefore hailed it as a breakthrough in the fight against obesity, one of our era’s most pressing public health problems. For several years, Novo Nordisk has been the sole provider of GLP-1 generation of weight loss drugs and it has heavily struggled to meet booming demand. ...

Is Novo Nordisk looking at the next generation of weight loss drugs?

To do so, Novo Nordisk’s CFO, Karsten Munk Knudsen, says the company is now looking at the next generation of weight loss drugs, which are expected to focus on specific subsets of the obese community. ...

How has wegovy boosted Novo Nordisk's profits?

Sales of Wegovy, an injectable prescription weight loss medicine, has helped boost profits for Novo ... [+] Novo Nordisk reported $33.7 billion of sales for 2023, an increase of 36% at constant exchange rates and beating analysts’ expectations. ...

Why did Novo Nordisk stock rise 45% in Q4?

Novo Nordisk shares rose 4.5% after a strong Q4 profit beat, driven by high demand for obesity drug Wegovy, despite forecasting slower sales growth for 2025. ...